Authors
Fabiola Olivieri, Ilaria Mazzanti, Angela M Abbatecola, Rina Recchioni, Fiorella Marcheselli, Antonio D Procopio, Roberto Antonicelli
Publication date
2012/3/1
Source
Current vascular pharmacology
Volume
10
Issue
2
Pages
216-224
Publisher
Bentham Science Publishers
Description
Statins are well established drugs for primary and secondary prevention of coronary artery disease (CAD). Despite the well-known ability of statins to lower cholesterol, it is now clear that clinical benefits are also substantially higher than expected and several clinical trials, like JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin trial) have indicated that such clinical effects are independent of cholesterol reduction. These cholesterol-independent actions have been named “pleiotropic effects” and include: anti-oxidation and anti-inflammatory effects, modulation of immune activation, stabilization of atherosclerotic plaque, decreased platelet activation, inhibition of cardiac hypertrophy, reduction of cytokine-mediated vascular smooth muscle cell (VSMC) proliferation and improvement of endothelial function. Recently, additional pleiotropic effects of statins on …
Total citations
201220132014201520162017201820192020202120222023202411111131064441412
Scholar articles
F Olivieri, I Mazzanti, AM Abbatecola, R Recchioni… - Current vascular pharmacology, 2012